These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 27784733)

  • 61. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; ; ;
    Circulation; 2004 Jul; 110(2):227-39. PubMed ID: 15249516
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
    Rosenson RS; Otvos JD; Freedman DS
    Am J Cardiol; 2002 Jul; 90(2):89-94. PubMed ID: 12106834
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.
    Otvos JD
    Clin Lab; 2002; 48(3-4):171-80. PubMed ID: 11934219
    [No Abstract]   [Full Text] [Related]  

  • 64. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
    Knowler WC; Barrett-Connor E; Fowler SE; Hamman RF; Lachin JM; Walker EA; Nathan DM;
    N Engl J Med; 2002 Feb; 346(6):393-403. PubMed ID: 11832527
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Variability in the response of HDL cholesterol to exercise training in the HERITAGE Family Study.
    Leon AS; Gaskill SE; Rice T; Bergeron J; Gagnon J; Rao DC; Skinner JS; Wilmore JH; Bouchard C
    Int J Sports Med; 2002 Jan; 23(1):1-9. PubMed ID: 11774059
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
    The Diabetes Prevention Program Research Group
    Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Individual variation in plasma cholesterol response to dietary saturated fat.
    Cox C; Mann J; Sutherland W; Ball M
    BMJ; 1995 Nov; 311(7015):1260-4. PubMed ID: 7496234
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.
    Warnick GR; Benderson J; Albers JJ
    Clin Chem; 1982 Jun; 28(6):1379-88. PubMed ID: 7074948
    [No Abstract]   [Full Text] [Related]  

  • 69. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
    Friedewald WT; Levy RI; Fredrickson DS
    Clin Chem; 1972 Jun; 18(6):499-502. PubMed ID: 4337382
    [No Abstract]   [Full Text] [Related]  

  • 70. Enzymatic methods for quantification of lipoprotein lipids.
    Warnick GR
    Methods Enzymol; 1986; 129():101-23. PubMed ID: 3724535
    [No Abstract]   [Full Text] [Related]  

  • 71. Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.
    Varga TV; Winters AH; Jablonski KA; Horton ES; Khare-Ranade P; Knowler WC; Marcovina SM; Renström F; Watson KE; Goldberg R; Florez JC; Pollin TI; Franks PW
    Circ Cardiovasc Genet; 2016 Dec; 9(6):495-503. PubMed ID: 27784733
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
    Goldberg RB; Mather K
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2077-90. PubMed ID: 22895669
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials.
    Chiavaroli L; de Souza RJ; Ha V; Cozma AI; Mirrahimi A; Wang DD; Yu M; Carleton AJ; Di Buono M; Jenkins AL; Leiter LA; Wolever TM; Beyene J; Kendall CW; Jenkins DJ; Sievenpiper JL
    J Am Heart Assoc; 2015 Sep; 4(9):e001700. PubMed ID: 26358358
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
    Musunuru K; Kathiresan S
    Circ Res; 2016 Feb; 118(4):579-85. PubMed ID: 26892959
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gene-environment interaction in dyslipidemia.
    Cole CB; Nikpay M; McPherson R
    Curr Opin Lipidol; 2015 Apr; 26(2):133-8. PubMed ID: 25692343
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Progress in genetic association studies of plasma lipids.
    Asselbergs FW; Lovering RC; Drenos F
    Curr Opin Lipidol; 2013 Apr; 24(2):123-8. PubMed ID: 23385652
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Polygenic risk scores for the diagnosis and management of dyslipidemia.
    Brunham LR; Trinder M
    Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):95-100. PubMed ID: 35034034
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exercise and lipids.
    Madan K; Sawhney JPS
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S73-S74. PubMed ID: 38599728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.